Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy

被引:16
|
作者
Monnier, L. [1 ]
Colette, C. [1 ]
Dejager, S. [2 ]
Owens, D. R. [3 ]
机构
[1] Univ Montpellier, Inst Clin Res, 641 Ave Doyen Giraud, F-34093 Montpellier 5, France
[2] Hosp Pitie Salpetriere, Dept Endocrinol, Paris, France
[3] Swansea Univ, Diabet Res Grp, Swansea, W Glam, Wales
来源
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS | 2016年 / 17卷 / 01期
关键词
Glucose homeostasis; Quality of diabetes therapy; GLYCEMIC VARIABILITY; MICROVASCULAR COMPLICATIONS; CARDIOVASCULAR OUTCOMES; DAWN PHENOMENON; PLASMA-GLUCOSE; VASCULAR COMPLICATIONS; MYOCARDIAL-INFARCTION; RECEPTOR AGONISTS; OXIDATIVE STRESS; BLOOD-GLUCOSE;
D O I
10.1007/s11154-016-9325-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Achieving near normal glucose homeostasis implies that all components of dysglycemia that are present in diabetes states be eliminated. Reducing ambient/overall hyperglycemia is a pre-requisite to eliminate the risk of development and progression of diabetes complications. More controversially however, are the relative and related contributions of postprandial glucose excursions, glucose variability, hypoglycemia and the dawn phenomenon across the spectrum of dysglycemia. For instance, it is likely that the dawn phenomenon contributes to ambient hyperglycemia and that postprandial glucose excursions are at the cross road of ambient hyperglycemia and glucose variability with glucose fluctuations as causative risk factors for hypoglycemia. Proof-of-concept trials such as the ongoing FLAT-SUGAR study are necessary for gaining further insight into the possible harmful effects of some of these features such as excessive glycemic variability and glucose excursions, still considered to be of minor relevance by several diabetologists. Whether their role will be more thoroughly proven through further intervention trials with "hard" endpoints, remains to be seen. In the meantime more consideration should be given to medications aimed at concomitantly reducing ambient/overall hyperglycemia and those additional abnormal glycemic features of dysglycemia.
引用
收藏
页码:91 / 101
页数:11
相关论文
共 50 条
  • [41] HbA1c screening for the diagnosis of diabetes
    Jan Brož
    Marek Brabec
    Pavlína Krollová
    Lucia Fačkovcová
    Juraj Michalec
    Diabetologia, 2023, 66 : 1576 - 1577
  • [42] HbA1c as a diagnostic tool for diabetes
    Balkau, B
    Forhan, A
    Simon, D
    Eschwege, E
    METABOLIC SYNDROME: DIABETES, OBESITY, HYPERLIPIDEMIA AND HYPERTENSION, 2003, 1253 : 19 - 26
  • [43] Use of HbA1c in screening for diabetes
    Roubicek, M
    Vines, G
    Sanguineti, AG
    DIABETES CARE, 1998, 21 (09) : 1577 - 1578
  • [44] HbA1c in the Evaluation of Diabetes Mellitus
    O'Keeffe, Derek T.
    Maraka, Spyridoula
    Rizza, Robert A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (06): : 605 - 606
  • [45] HbA1c screening for the diagnosis of diabetes
    Broz, Jan
    Brabec, Marek
    Krollova, Pavlina
    Fackovcova, Lucia
    Michalec, Juraj
    DIABETOLOGIA, 2023, 66 (08) : 1576 - 1577
  • [46] The Use of HbA1c for the Diagnosis of Diabetes
    Bonora, Enzo
    CURRENT DIABETES REPORTS, 2011, 11 (06) : 470 - 471
  • [47] HBA1C FOR DIABETES MELLITUS DIAGNOSIS
    Dzebisashvili, T.
    JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2011, 65 : A330 - A331
  • [48] HbA1c and Diabetes: Mismatches and Misclassifications
    Rhee, Mary
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (07): : E2630 - E2632
  • [49] Prediction of diabetes mellitus using HbA1c: Does HbA1c more efficiently predict onset than plasma glucose concentration?
    Tanabe, N.
    Yamamoto, M.
    Momotsu, T.
    Suzuki, K.
    Sanpei, K.
    Sone, H.
    DIABETOLOGIA, 2013, 56 : S122 - S122
  • [50] The Use of HbA1c for the Diagnosis of Diabetes
    Enzo Bonora
    Current Diabetes Reports, 2011, 11 : 470 - 471